Recent study shows 400 mg dose of Peak ATP supports exercise and performance, says TSI Group

Photo © iStockphoto.com/Ibrakovic

A recent, unpublished, randomized, placebo-controlled, dose-ranging crossover study conducted by researchers at Brazil’s Federal University of Piauí evaluated the benefits of 100 mg, 200 mg, and 400 mg doses of Peak ATP, a patented form of Adenosine 5’-Triphosphate (ATP) Disodium, administered orally as a premix powder. In the study, 20 recreationally trained men in their late 20s completed four sets of resistance training exercise until movement failure with two minutes of rest between sets.

Results showed that a single 400 mg dose ATP improved lower body resistance training performance and energy expenditure, increasing the number of set 1 repetitions by 13% and numerical increases in total repetitions by 7%, and total weight lifted by 6%. An ATP dose of 200 mg numerically increased set 1 repetitions by 6%, while 100 mg of ATP saw no improvements over placebo. However, subjects taking 100 mg and 400 mg of ATP saw the lowest perceived exertion, while those taking 200 mg experience the highest perceived exertion.

“These results confirm the immediate benefits of Peak ATP for athletes, weekend warriors and everyday exercisers,” said Larry Kolb, TSI Group president, in a press release. “We feel that there is a huge advantage for consumers who are able to feel the performance benefit from the first use onward, instead of waiting for weeks for supplementation to take full effect. Peak ATP helps exercisers to push harder during high-intensity and/or exhaustive exercise. And because Peak ATP supports increased work volume, it can help anyone make the most of time spent exercising. This is crucial to helping everyday people exercise harder and more frequently as they pursue their long-term wellness goals.”